Azilsartan medoxomil was approved by the United States Food and Drug Administration in 2011. AZL is used for the treatment of essential hypertension and has publicized promising results in blood pressure (BP) reduction and tolerability, but has not yet been considered into practice as compared to other angiotensin II receptor blockers (ARBs). AZL lowers blood pressure by blocking the action of angiotensin II at the AT1 receptor, a hormone that contracts blood vessels and reduces water excretion through the kidneys. There have been numerous methods developed so far for quantitative estimation of AZL in bulk and pharmaceutical dosage form. Pharmaceutical analytical methods include UV Visible Spectrophotometry, High Pressure Thin Layer Chromatography, Reversed Phase High Performance Liquid Chromatography and hyphenated techniques like Liquid chromatography- Mass Spectrometry. This review paper includes publications form 2010 to 2018. The chromatographic methods primarily RP-HPLC and LC-MS found more accurate, precise and sensitive compared to other pharmaceutical methods. AZL shows greater extent of degradation up to 40% with hydrogen peroxide. AZL is degraded up to 38% and 31% with acidic and neutral pH respectively while it shows greater photo stability and dry heat.
Cite this article:
Prashant B. Patil. Azilsartan: A Review of Analytical Methods for estimation in Pharmaceutical Formulation. Asian J. Pharm. Ana. 2018; 8(4): 227-232. doi: 10.5958/2231-5675.2018.00041.8
Prashant B. Patil. Azilsartan: A Review of Analytical Methods for estimation in Pharmaceutical Formulation. Asian J. Pharm. Ana. 2018; 8(4): 227-232. doi: 10.5958/2231-5675.2018.00041.8 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2018-8-4-9